Detalhe da pesquisa
1.
Is re-challenge still an option as salvage therapy in multiple myeloma? The case of REal-life BOrtezomib re-Use as secoND treatment for relapsed patients exposed frontline to bortezomib-based therapies (the REBOUND Study).
Ann Hematol
; 98(2): 361-367, 2019 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-30353388
2.
Cyclophosphamide's addition in relapsed/refractory multiple myeloma patients with biochemical progression during lenalidomide-dexamethasone treatment.
Eur J Haematol
; 2018 May 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29719938
3.
A prospective observational study to assess clinical decision-making, prognosis, quality of life and satisfaction with care in patients with relapsed/refractory multiple myeloma: the CLARITY study protocol.
Health Qual Life Outcomes
; 16(1): 127, 2018 Jun 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-29914509
4.
Patient-reported outcomes in relapsed/refractory multiple myeloma: a systematic review.
Support Care Cancer
; 26(7): 2075-2090, 2018 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-29560502
5.
Autologous transplantation and maintenance therapy in multiple myeloma.
N Engl J Med
; 371(10): 895-905, 2014 Sep 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-25184862
6.
Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study.
Blood
; 124(1): 63-9, 2014 Jul 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-24855212
7.
Arterial and venous thrombosis in patients with monoclonal gammopathy of undetermined significance: incidence and risk factors in a cohort of 1491 patients.
Br J Haematol
; 160(5): 673-9, 2013 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-23240810
8.
Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials.
Blood
; 118(5): 1239-47, 2011 Aug 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-21670471
9.
Genome-wide analysis of primary plasma cell leukemia identifies recurrent imbalances associated with changes in transcriptional profiles.
Am J Hematol
; 88(1): 16-23, 2013 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-23044976
10.
Prognostic factors associated with progression of smoldering multiple myeloma to symptomatic form.
Cancer
; 118(22): 5544-9, 2012 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-22786730
11.
Melphalan 200 mg/m(2) versus melphalan 100 mg/m(2) in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study.
Blood
; 115(10): 1873-9, 2010 Mar 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-19965659
12.
Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial.
Haematologica
; 97(5): 784-91, 2012 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-22133776
13.
Advanced chronic myelomonocytic leukemia in elderly and frail patients managed by azacitidine in the field of clinical practice.
Ann Hematol
; 96(9): 1591-1593, 2017 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-28702776
14.
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.
Lancet
; 376(9758): 2075-85, 2010 Dec 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-21146205
15.
Towards a better understanding of the relationship between side effects of analgesia and quality of life in patients with multiple myeloma.
Support Care Cancer
; 24(1): 9-10, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26238628
16.
Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial.
Blood
; 112(8): 3107-14, 2008 Oct 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-18505783
17.
Chronic myelomonocytic leukemia coexisting with monoclonal gammopathy: concomitant response to azacitidine of both disorders.
Ann Hematol
; 94(10): 1753-4, 2015 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26088814
18.
Considerations in the treatment of multiple myeloma: a consensus statement from Italian experts.
Eur J Haematol
; 82(2): 93-105, 2009 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-19018865
19.
Dysgeusia in patients with hematological malignancies: a reminder for hematologist.
J Oral Pathol Med
; 42(4): 352-3, 2013 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-23278835
20.
Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis.
J Cancer Res Clin Oncol
; 144(7): 1357-1366, 2018 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-29675792